Evidence map›Paper›PMID 39954727›Full record

ArticleThe journal of allergy and clinical immunology. In practice2025

α

Victor E Ortega, Vickram Tejwani, Abhishek Kumar Shrivastav, Sara Pasha, Joe G Zein, Meher Boorgula, Mario Castro, Loren Denlinger, Serpil C Erzurum, John V Fahy and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Alpha1-Antitrypsin in Lung Diseases: A Cross-Sectional Observational Study.International journal of molecular sciences · 2025
    Observational
  6. Review
  7. Impact of Saharan Dust andInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Victor E OrtegaDepartment of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Scottsdale, Ariz. Electronic address: Ortega.Victor@mayo.edu.
Vickram TejwaniDepartment of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio; Department of Systems Biology and Genome Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Abhishek Kumar ShrivastavDepartment of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Scottsdale, Ariz.
Sara PashaDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Kentucky, Lexington, Ky.
Joe G ZeinDepartment of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Scottsdale, Ariz.
Meher BoorgulaDepartment of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colo.
Mario CastroDepartment of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas Medical Center, Kansas City, Kan.
Loren DenlingerDepartment of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, Wis.
Serpil C ErzurumDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
John V FahyDepartment of Medicine, University of California San Francisco, San Francisco, Calif.
Elliot IsraelDepartment of Pulmonary and Critical Care Medicine and Allergy and Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Nizar N JarjourDepartment of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, Wis.
Bruce LevyDepartment of Pulmonary and Critical Care Medicine and Allergy and Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
David MaugerDivision of Biostatistics and Bioinformatics, Department of Public Health Sciences, Pennsylvania State University, University Park, Pa.
Wendy C MooreDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC.
Sally E WenzelDepartment of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pa.
Prescott WoodruffDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, Calif.
Gregory A HawkinsDepartment of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC.
Eugene R BleeckerDepartment of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Scottsdale, Ariz.
Deborah A MeyersDepartment of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Scottsdale, Ariz.
NHLBI Severe Asthma Research Program (SARP)

Funding

Severe Asthma Research ProjectR01HL069174 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WENZEL, SALLY E · 2001 to 2010
$9.2M
Clinical Coordinating Center for the Severe Asthma Research Program (SARP)U10HL109086 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MAUGER, DAVID T. · 2011 to 2017
$8.1M
Severe Asthma From Respiratory InfectionsR01HL069116 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI BUSSE, WILLIAM W. · 2001 to 2010
$7.6M
Non-coding RNA structure change in Chronic Obstructive Pulmonary DiseaseR01HL111527 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Alain T Laederach, Kevin M Weeks · 2012 to 2026
$6.6M
Genotype-Phenotype Interactions in Severe AsthmaR01HL069167 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BLEECKER, EUGENE ROLAND · 2001 to 2010
$5.5M
Redox Determinants of Severe AsthmaR01HL069170 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ERZURUM, SERPIL C. · 2001 to 2010
$5.1M
AMSA: ALXR/FBR Mediated Signaling in Severe AsthmaU10HL109172 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ISRAEL, ELLIOT, LEVY, BRUCE D · 2011 to 2016
$4.2M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Clinical and Molecular Phenotypes of Severe AsthmaU10HL109146 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2011 to 2016
$4.0M
Implications and Stability of Clinical and Molecular Phenotypes of Severe AsthmaU10HL109152 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WENZEL, SALLY E · 2011 to 2016
$3.9M
Stability of Severe Asthma Phenotypes: Impact of ExacerbationsU10HL109168 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI JARJOUR, NIZAR N · 2011 to 2016
$3.9M
Severe Asthma Research Program (SARP)-Washington UniversityU10HL109257 · NHLBI · WASHINGTON UNIVERSITY · PI CASTRO, MARIO · 2011 to 2016
$3.8M
NHLBI NIH HHS K08 HL118128NHLBI NIH HHS R01 HL069116NHLBI NIH HHS R01 HL069167NHLBI NIH HHS R01 HL069170NHLBI NIH HHS R01 HL069174NHLBI NIH HHS R01 HL111527NHLBI NIH HHS R01 HL142992NHLBI NIH HHS R01 HL161674NHLBI NIH HHS U10 HL109086NHLBI NIH HHS U10 HL109146NHLBI NIH HHS U10 HL109152NHLBI NIH HHS U10 HL109164NHLBI NIH HHS U10 HL109168NHLBI NIH HHS U10 HL109172NHLBI NIH HHS U10 HL109250NHLBI NIH HHS U10 HL109257
6 · The paper itself

Abstract

backgroundα

objectiveTo characterize the influence of SERPINA1 variation on asthma severity.

methodsDNA samples from 847 non-Hispanic White and 446 African American participants from the Severe Asthma Research Program underwent SERPINA1 resequencing to identify rare variants. An independent population of 1955 individuals with asthma and α

resultsIn White participants, a history of minimum smoking significantly interacted with SERPINA1 low-to-rare frequency variation to determine risk for asthma-related health care utilization. This was attributed to protease inhibitor type Z heterozygotes (MZ, N = 11), who had a higher frequency of emergency department (ED) visits (6 [54.5%] MZ heterozygotes, odds ratio [OR] = 7.60, 95% confidence interval [CI] = 1.71-39.7, P = .010), hospitalization (5 [45.5%], OR = 16.1, 95% CI = 2.64-150.4, P = .0050) in the past year, and lifetime intensive care unit (ICU) admissions (6 [54.5%], OR = 12.5, 95% CI = 2.44-75.6, P = .0032) compared with 146 individuals without SERPINA1 variants (30 [20.5%] reporting ED visits, 17 [11.6%] hospitalization, and 15 [10.3%] ICU admission). SERPINA1 variant-by-ever smoking interactions in African American participants for ED visits (P = .069) were related to 4 of 6 compound heterozygotes reporting an ED visit. In CCHS, α

conclusionsSERPINA1 variation and α

Indexed as

alpha 1-AntitrypsinAsthmaPatient Acceptance of Health CareAdultAgedalpha 1-Antitrypsin DeficiencyBlack or African AmericanFemaleGene-Environment InteractionGenetic Predisposition to DiseaseGenetic VariationHumansMaleMiddle AgedSeverity of Illness IndexSmokingalpha 1-AntitrypsinSERPINA1 protein, humanAlpha1-antitrypsinAsthmaExacerbationsGeneticsLung functionRare variantSERPINA1

Identifiers

PMID39954727
PMCPMC13285010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.